(PFNX) |
| 0 (0%) 01-13 20:33 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 15.13 |
| Resistance 1: | 12.95 |
| Pivot price: | 12.73 |
| Support 1: | 12.67 |
| Support 2: | 12.50 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | -0.100 |
| Book Value | 2.430 |
| PEG Ratio | 0.00 |
| Gross Profit | 1.325 |
| Profit Margin (%) | -7.03 |
| Operating Margin (%) | -7.53 |
| Return on Assets (ttm) | -2.5 |
| Return on Equity (ttm) | -4.3 |
Company news
Fri, 09 Jan 2026
New Research: Key Drivers of Growth for Capital One Financial, ServiceSource International, Pfenex, eMagin, Interpace Diagnos... - ADVFN
Mon, 10 Aug 2020
Ligand to Acquire Pfenex Inc. - Business Wire
Tue, 08 Oct 2019
US competition brewing for Lilly's Forteo blockbuster - The Pharma Letter
Mon, 08 Aug 2016
Pfizer returns rights to Pfenex for Lucentis biosimilar - Fierce Biotech
Fri, 19 Jun 2015
Biosimilar of Novartis' eye drug Lucentis launched in India - Fierce Pharma
Tue, 13 Jan 2026
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
